Sugammadex Versus Neostigmine After Rocuronium Continuous Infusion in Patients Undergoing Liver Transplantation.

CURRENT STATUS: UNDER REVIEW

SUGAMMADEX VERSUS NEOSTIGMINE AFTER ROCURONIUM CONTINUOUS INFUSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION.

Preprint: Please note that this article has not completed peer review.

CRISTIAN DEANA
Azienda Sanitaria Universitaria Integrata di Udine
DEANA.CRISTIAN@GMAIL.COM
Corresponding Author
ORCiD: 0000-0002-1626-3177

Federico Barbariol
Azienda Sanitaria Universitaria Integrata di Udine

Stefano D’Incà’
Azienda per l’Assistenza Sanitaria n 3 Alto Friuli Collinare Medio Friuli

Livia Pompei
Azienda Sanitaria Universitaria Integrata di Udine

Giorgio Della Rocca
Università degli Studi di Udine

DOI:
10.21203/rs.2.11130/v3

SUBJECT AREAS
Hepatobiliary & Transplant Surgery

KEYWORDS
rocuronium, neostigmine, reversal, recovery time, liver transplantation
Abstract

Background: Rapid neuromuscular block reversal at the end of major abdominal surgery is recommended to avoid any postoperative residual block. To date, no study has evaluated sugammadex performance after rocuronium administration in patients undergoing liver transplantation.

This is a randomized controlled trial with the primary objective of assessing the neuromuscular transmission recovery time obtained with sugammadex versus neostigmine after rocuronium induced neuromuscular blockade in patients undergoing orthotopic liver transplantation.

Methods: The TOF-Watch SX®, calibrated and linked to a portable computer equipped with TOF-Watch SX Monitor Software®, was used to monitor and record intraoperative neuromuscular block maintained with a continuous infusion of rocuronium. Anaesthetic management was standardized as per our institution's internal protocol. At the end of surgery, neuromuscular moderate block reversal was obtained by administration of 2 mg/kg of sugammadex or 50 mcg/kg of neostigmine (plus 10 mcg/kg of atropine).

Results: Data from 41 patients undergoing liver transplantation were analysed. In this population, recovery from neuromuscular block was faster following sugammadex administration than neostigmine administration, with mean times±SD of 9.4±4.6 min and 34.6±24.9 min, respectively (p<0.0001).

Conclusion: Sugammadex is able to reverse neuromuscular block maintained by rocuronium continuous infusion in patients undergoing liver transplantation. The mean reversal time obtained with sugammadex was significantly faster than that for neostigmine. It is important to note that the sugammadex recovery time in this population was found to be considerably longer than in other surgical settings, and should be
considered in clinical practice.

Trial registration: ClinicalTrials.gov NCT02697929 (registered 3rd March 2016).

Background

Myoresolution plays a crucial role in laparotomic and laparoscopic general surgery, including orthotopic liver transplantation (OLT), where a deep level of neuromuscular block (NMB) has been shown to provide better surgical conditions.\(^1,\,2\) Deep NMB, defined as ≤ 2 responses after post-tetanic stimulation (or ‘post-tetanic count’, PTC), requires higher doses of a neuromuscular blocking drug (NMBD), with a consequent higher risk of longer and unpredictable recovery times regardless of the agent used.\(^3\)-\(^5\) The use of NMBD at high dosages to achieve deep NMB may also be associated with increased postoperative residual curarization (PORC) that leads to pulmonary complications and may even hinder successful extubation\(^6\)-\(^8\). Both the administration of NMBD reversal agents at the end of surgery and the use of neuromuscular transmission (NMT) monitoring throughout the surgical procedure are key factors to counteract the adverse outcomes related to impaired neuromuscular transmission after extubation\(^9\)-\(^11\),\(^12\). International guidelines and expert opinions strongly recommend NMT monitoring to optimize the dosage and timing of both NMBD and reversal agent administration, with the upshot of enabling early and safe extubation. This is also strongly encouraged in OLT settings, due to it being able to affect patient outcome directly as well as being a cost-effective practice\(^13\)-\(^18\).

The pharmacokinetics and pharmacodynamics of rocuronium bromide may be altered in patients with impaired liver function, resulting in a longer elimination half-life, a slower recovery from NMBD and unpredictable behaviour for instance about onset time\(^19\),\(^20\). The safety and speed of action of sugammadex has been investigated and validated in
different settings, including patients with liver disease undergoing liver surgery\textsuperscript{21-23}. Fujita and colleagues demonstrated that sugammadex can be effective for the reversal of NMBD after low dose rocuronium continuous infusion in patients with liver disorders undergoing liver resection surgery, with no differences between cirrhotic and non-cirrhotic patients, as supported by comparable sugammadex recovery times between the two groups of patients\textsuperscript{24}. Similar results were recently obtained by Abdulatif and colleagues who recorded a mean recovery time of 3.1 minutes for sugammadex given at a dose of 2 mg/kg for moderate block reversal in a cohort of patients with chronic hepatitis C liver cirrhosis undergoing liver resection surgery for neoplastic lesions\textsuperscript{25}. However, patients with end-stage liver disease undergoing OLT may present some features that make the pharmacodynamics of rocuronium even more unpredictable; such features may include: extensive blood loss; need for urgent surgery; long length of surgery; extensive fluid shifts; large haemodynamic changes with consequent variable organ perfusion (including emunctory organs).

To the best of our knowledge, no study has evaluated sugammadex use after the continuous infusion of rocuronium during OLT. The primary objective of this study was to measure the time interval from the administration of the NMBD reversal agent (sugammadex or neostigmine) to a train-of-four ratio ($\text{TOF}_R \geq 0.9$) (i.e., the recovery time) in patients who had undergone OLT with intraoperative continuous rocuronium infusion. The secondary objective was to determine possible relationships between the recovery times of the two drugs with pre-, intra- or postoperative variables.

**Methods**

This is a single centre, non-blinded, randomized controlled trial approved by our Institution’s Ethics Committee (CEUR 2016-0-015-ASUIUD) and registered at
ClinicalTrials.gov (NCT02697929) prior to patient enrolment. This manuscript adheres to the applicable CONSORT guidelines and the study protocol conformed to the Declaration of Helsinki ethical guidelines.

After ClinicalTrial.gov registration, we evaluated consecutive cases of OLT performed at the Academic Hospital “S. Maria della Misericordia”, Udine, Italy. Written informed consent was obtained before commencing OLT; patients were then randomly allocated to the sugammadex or neostigmine group using an online computer-generated table. All clinical data were collected in an Excel spreadsheet (Microsoft Excel for Mac, Version 14.0.0, Microsoft Corporation, USA). Inclusion criteria were as follows:

Age > 18 years
Neuromuscular transmission data acquired with TOF-Watch SX Monitor Software® (Organon, Dublin, Ireland. Version 1.2), from anaesthesia induction until extubation

Exclusion criteria were as follows:
American Society of Anesthesiologists (ASA) status > 3
Neuromuscular disease
NMBA other than rocuronium bromide used
Body mass index (BMI) < 18 kg/m² or > 40 kg/m²
Pre-operative impaired renal function, defined as an estimated glomerular filtration rate < 30 ml/min/1.73 m²
Incorrect dosage of reversal (50 mcg/kg for neostigmine and 2 mg/kg for sugammadex)
An inner body temperature < 35°C or thenar temperature < 32°C at reversal administration
Haemodynamic instability defined as norepinephrine dosage > 0.1 mcg.kg⁻¹.min⁻¹ and/or dobutamine > 3 mcg.kg⁻¹.min⁻¹ and/or epinephrine > 0.1 mcg.kg⁻¹.min⁻¹ at the time of reversal administration and/or mean arterial pressure < 60 mmHg and/or HR > 100 bpm
Acidosis defined as an arterial pH < 7.30 at the time of reversal administration

The last three exclusion criteria were also applied to determine whether extubation at the end of surgery could be attempted in the operating room in cases in which no graft dysfunction was present.

The pre-operative data collected regarded: sex; age; weight; body mass index (BMI); liver disease; model for end-stage liver disease (MELD); liver function; and renal function. The intra-operative data collected regarded: duration of surgery; intra-operative blood losses;
packet red cells (PRC); fresh frozen plasma (FFP) and salvage blood transfused; platelets (PLT) use; fibrinogen administration; net fluid balance; cold ischaemia time (CIT); warm ischaemia time (WIT); total dose of rocuronium administered; and total millilitres of crystalloids and colloids infused. Cardiac output, cardiac index and central temperature (values obtained from the pulmonary artery catheter) with thenar temperature at the time of reversal administration were also recorded. Any adverse events were reported in the anaesthesia sheet.

Anaesthesia was induced with propofol (1-1.5 mg/kg) and fentanyl (3-5 mcg/kg) or alfentanil (7-15 mcg/kg) after facial mask denitrogenation with F\textsubscript{1}O\textsubscript{2}=0.8. NMBD (rocuronium 0.6 mg.kg based on lean body weight) was administered at anaesthesia induction only after TOF Watch SX® calibration (Organon, Dublin, Ireland). Anaesthesia was maintained with sevoflurane (End Tidal [ET%] targeted to keep the bispectral index in the 40-60 range) and the continuous infusion of remifentanil (0.05-0.3 mcg.kg\textsuperscript{-1}.min\textsuperscript{-1}), while neuromuscular block was maintained by continuous intravenous infusion of rocuronium bromide (Esmeron® 50 mg/5 mL, MSD Italia S.r.l., Roma) (0.3-0.6 mg.kg\textsuperscript{-1}.h\textsuperscript{-1}) to keep T\textsubscript{1} <1 0%. Haemodynamic monitoring, using a pulmonary artery catheter (CCombo catheter 777HF8; Edwards Lifescience, Irvine, California, USA), aimed to optimize indexed oxygen delivery (DOI\textsubscript{2} > 600 ml.min\textsuperscript{-1}.m\textsuperscript{2}) for the first 6 hours postoperatively. All OLT were performed with the same surgical equipe dedicated to solid organ transplant surgery. As per our routine practice for NMT monitoring with TOF-Watch, two electrodes were placed over the left ulnar nerve at the wrist and the acceleration transducer put on the thumb, together with a hand adapter that immobilized the other fingers. Data were collected using a dedicated computer and TOF-Watch SX Monitor Software®, which registered the response to ulnar nerve stimulation every 15 s. After anaesthesia induction,
but before rocuronium administration, the TOF-Watch SX was calibrated. Once calibration was complete, the rocuronium bolus for tracheal intubation was administered and continuous infusion started.

At the end of surgery, reversal agents – sugammadex 2 mg/kg based on actual body weight (Bridion® 100 mg/mL, MSD Rome, Italy) or neostigmine 50 mcg/kg based on adjusted body weight plus 10 mcg/kg of atropine (Intrastigmina®, 0.5 mg/mL, Lusofarmaco S.p.a., Rozzano, Italy) – were administered (according to randomization) after the appearance of three consecutive T2 Twitches (the so called moderate neuromuscular block; T2) detected by TOF Watch SX®. Recovery time was defined as the time interval from the administration of the reversal agent to the achievement of 3 consecutive measurements of \( \text{TOF}_R \geq 0.9 \).

Our secondary objective was to analyse the main possible correlations between factors that may have influenced sugammadex and neostigmine recovery time: BMI; MELD; pre-operative and postoperative liver and renal function; surgical procedure length; blood loss; intraoperative fluid balance; cold and warm ischaemia time; total amount of NMBA delivered; millilitres of crystalloid and colloid infused; CO and CI at the time of reversal administration.

**Statistical Analysis**

Illman and colleagues found a mean difference of 11.6 minutes between sugammadex and neostigmine recovery times, administered when two Twitches were detectable and reversal considered as having occurred when \( \text{TOF}_R > 90\% \). Considering a 1:1 treatment ratio and an expected 5-minute reduction in the sugammadex group, with an alpha level of 0.05 and a power (1-\( \beta \)) of 90%, the calculated sample size was 16 subjects for each group. Taking into consideration a potential dropout of 20% and to increase the statistical significance,
we decided to enrol at least 20 subjects per group.

Descriptive statistics (mean and standard deviation for quantitative variables, and absolute and relative frequencies for qualitative variables) were calculated for each group. To test for a difference in the recovery times between the two groups with respect to the primary objective, we implemented a two-sided unpaired t test as well as an F-test to compare variances and to test whether the t test assumptions were met. The same test was applied to all remaining data. The alpha level of statistical significance for all applied tests was 0.05. No imputation of missing data was used in the analysis. Finally, to detect possible relationships between the recovery times of the two drugs with other variables, we performed both the Spearman rank and the Pearson correlation tests, since differences, or a lack thereof, could provide additional information.

GraphPad Prism version 6.01 (GraphPad Software, California, USA) was used for the final statistical analysis.

Results

A total of 41 patients were enrolled onto the study: 21 were treated with sugammadex and 20 with neostigmine, as shown in the study flowchart (Figure 1). Baseline characteristics and end-stage liver disease aetiology were comparable between the sugammadex and neostigmine groups (Table 1). Furthermore, there were no statistically significant differences in pre-, intra- or postoperative values regarding haemodynamics, liver and renal function (Table 1 and 2).

The rocuronium onset times were similar between the two groups at 195±124 and 250±123 seconds for the sugammadex and neostigmine groups, respectively ($p=0.20$).

The total dose of rocuronium administered was 217±61 mg and 199±74 mg ($p=0.41$) for the sugammadex and neostigmine groups, respectively. The total amount of reversal administered was 147±25.5 mg and 3.7±0.6 mg, respectively.
The mean core and thenar site temperatures of patients treated with sugammadex, recorded at reversal administration, were 37±0.8°C and 35.2±1.3°C, respectively; whereas they were 36.6±0.9°C and 35.2±1.4°C in the neostigmine group (core $p=0.29$, thenar site $p=0.92$).

The mean time from ceasing rocuronium infusion to T2 was 57±32 and 58±25 min in the sugammadex and neostigmine groups, respectively ($p=0.95$). Mean recovery times were significantly faster in patients treated with sugammadex than neostigmine: 9.4±4.6 min vs. 34.6±24.9 min, respectively ($p<0.0001$), as shown in Figure 2. Seven patients out of 21 (33%) in the sugammadex group required more than 10 minutes to achieve a $\mathrm{TOF}_{R}>0.9$. One patient in the neostigmine group was an outlier with a recovery time > 100 minutes and as such was not included in the mean recovery time calculation (figure 2).

In the sugammadex group, 4 patients were extubated at the end of surgery in the operating room (19%); this occurred in 2 patients in the neostigmine group (10%, $p=0.41$). No difference was observed in the time from ICU admission to extubation (245±22 min vs. 265±62 min in the sugammadex and neostigmine groups, respectively, $p=0.44$).

Two patients (9.5%) in the sugammadex group and 1 patient (5%) in the neostigmine group underwent re-operation within 24 hours of extubation. In all cases, intra-abdominal haemorrhage was responsible for the redo surgery, and rapid sequence induction with succinylcholine was performed before administering cisatracurium.

The results of the coagulation tests performed before and at the end of surgery were as follows: neostigmine group: pre- vs. post operative INR: 2±0.7 vs. 1.5±0.4, respectively ($p=0.01$); pre- vs. post operative aPTT ratio: 1.5±0.5 vs. 1.2±0.2, respectively ($p=0.04$).

The same tests relative to the sugammadex group were as follows: pre- vs. post operative INR: 1.6±0.7 and 1.5±0.5, respectively ($p=0.71$); pre- vs. post operative aPTT ratio: 1.3±0.4 vs. 1.3±0.2, respectively ($p=0.43$).
We also investigated the existence of correlations between recovery time and BMI, MELD, duration of surgery, WIT, C1T, PLT, fibrinogen, fluid balance, amount of intravenous fluids administered, liver function, creatinine clearance pre or post-surgery and total amount of NMBDs administered. No evidence for any strong correlations were found using Pearson and Spearman tests (Table 3). Only a positive trend was highlighted that might denote a possible moderate correlation between sugammadex recovery time and: AST post OLT (r=0.61, p=0.003); ALT post OLT (r=0.50, p=0.02); and amount of colloids (r=0.50, p=0.02). In the neostigmine group, only length of surgery showed a possible moderate correlation with recovery time (r=0.57, p=0.009). No adverse events were reported for either group.

Discussion

The present study constitutes the first randomized controlled trial to evaluate sugammadex use following a rocuronium bolus and continuous infusion in the OLT setting. Our main finding is that, as was expected, sugammadex results in a considerably shorter recovery time than neostigmine, although the absolute value was longer than expected, considering previously reported data in the literature regarding other (non OLT) operative settings. The mean recovery time for sugammadex in our population was 9.4 min, which is longer than that reported in other studies after sevoflurane anaesthesia\textsuperscript{15}, with 33% of patients requiring more than 10 minutes to achieve a \( \text{TOF}_R > 0.9 \). This should be taken into account in clinical practice when waking patients up at the end of transplantation. However, sugammadex retained its well-known advantage as it regards recovery time over neostigmine, which had a mean recovery time of 34.6 min. Of important note is the fact that 19% of the patients in the neostigmine group required more than 60 minutes to recover from NMB, with a maximum value that exceeded 100 minutes. Previous studies
using rocuronium-sugammadex in patients affected by liver disease undergoing hepatic resection have demonstrated the well-known advantages of sugammadex over neostigmine in the above-mentioned setting\textsuperscript{24-25}. However, OLT differs greatly from general surgery or liver resection surgery; for instance, blood loss and duration of surgery may be significantly greater in OLT. Furthermore, the severity of the liver disease can play a role: the patients enrolled onto our study were more critical than those enrolled by Fujita and colleagues\textsuperscript{24} and Abdutalif and colleagues\textsuperscript{25} given their end-stage liver disease (see the AST and ALT, bilirubin, serum albumin and gamma glutamyl transferase values for example). In addition, in the study by Fujita and colleagues, rocuronium continuous infusion was targeted at obtaining T1 at TOF-stimulation, a lower degree of NMB compared with our study, in which deep NMB was achieved. These findings probably explain the lower total dose of rocuronium infused in the above-cited studies compared with our study. Moreover, some evidence exists in the literature, considering various operative settings, to suggest that higher total doses of rocuronium may be related to longer recovery times; for example, Llaurado and colleagues described a relationship between total rocuronium dose and recovery time in a cohort of obese patients following sugammadex administration\textsuperscript{27}. Abdulatif and colleagues demonstrated the safe use and efficacy of sugammadex in the specific setting of cirrhotic patients with a mean recovery time of 3.1 min\textsuperscript{25}. The higher rocuronium dosage used in the present study compared with that by Abdulatif et al. could, in part, explain our longer recovery times. It should also be noted, however, that the total duration of surgery required in our setting was significantly longer than in the cases considered by Abdulatif et al.; we administered rocuronium via continuous infusion at a fixed dose (in accordance with the study protocol), a modality
that could have overexposed the patient (for instance in the anhepatic phase) to the NMBD.

In the literature, an experimental study has investigated the possibility of interactions occurring between sugammadex and other drugs, and indeed it has been found that flucloxacillin, fusidic acid and tormifene have the potential to exert a displacement interaction with sugammadex. An in vitro study has also demonstrated possible interferences between corticosteroids and sugammadex action, whereas, Rezonja and colleagues, published an in vivo randomized controlled trial in which they demonstrated that dexamethasone does not alter sugammadex recovery time. The opposite was later concluded by Saleh and colleagues, who, evaluating dexamethasone use for the prevention of post-operative nausea and vomiting in children undergoing strabismus surgery, demonstrated a delayed reversal of rocuronium-induced NMB by sugammadex. To make the picture even more complex, it was recently demonstrated by Ozer and colleagues that sugammadex recovery times are reduced when administered in conjunction with steroids, especially desamethasone. All the patients in our study received a high intraoperative dose (3.5-5 mg/kg) of methylprednisolone hemisuccinate as immunosuppressant just before hepatic vascular unclamping. In an experimental study on rats, Saleh and colleagues evaluated the effect of very high (non clinical) steroid dosages on the resulting behaviour of sugammadex on rocuronium, but, once again, no significant affect was detected. Human studies into the potential interference between corticosteroids and sugammadex action are still lacking. Kandemir and colleagues, in their animal study, found that when methylprednisolone was used in combination with remifentanil, sugammadex action was prolonged due to a synergistic effect. This result contrasts with that reported by Zwiers and colleagues, in which these two drugs were
used individually and no alterations in the clinical effect of sugammadex were reported\textsuperscript{28}. However, in the different context of OLT, the pharmacokinetics of remifentanil are best described by a two-compartment model that takes into account a central and a peripheral volume of distribution. In addition, the functional status of the liver did not significantly affect the pharmacokinetics of remifentanil, although body weight also influences the volumes of distribution with implications for the pharmacokinetic behaviour of remifentanil\textsuperscript{34}. These findings are very intriguing and require further research since the volume of distribution after OLT may be deeply altered - often increased - and could, therefore, lead to the redistribution of remifentanil and, consequently, to the possible interaction between remifentanil-methylprednisolone and sugammadex function following liver reperfusion. However, this is only a speculative proposal to explain the longer recovery times of sugammadex in OLT. To understand the unexpected relatively long recovery time of sugammadex in more detail, we performed Pearson and Spearman tests to explore the possible correlations between peri-operative variables and recovery time, but no statistically significant strong correlations were found (Table 3). However, postoperative liver AST and ALT, and the amount of intra-operative colloids were found to show a positive trend with shorter sugammadex recovery times, denoting a possible moderate correlation. Intra-operative colloids may influence cardiac output. Thus, higher amounts of colloid administration could result in a faster redistribution of rocuronium from the peripheral compartment into the central one, where it is then encapsulated by sugammadex and eliminated by the kidney. It may also be possible that graft function influences sugammadex performance, since rocuronium is mostly eliminated by liver uptake, thus contributing to the elimination of NMB by adding to the action of sugammadex. However, the sample size of this study was not calculated with the view of
investigating these potential interactions with sugammadex, so further randomized
tables of adequate numerosity will be required to understand these possibilities
any further. The pharmacokinetics of rocuronium are highly variable in cirrhotic patients,
with some authors noting longer onset and offset times. Given this premise, a
physician might argue against its use in patients undergoing OLT, in favour of a non-
organ-specific metabolized NMB, such as cisatracurium, with a more favourable
metabolism. However, the possibility of rapidly reversing rocuronium activity with
sugammadex offers advantages in the context of fast track surgery in general and in OLT
in particular, providing anaesthetists with the possibility of extubating the patient in the
operating room or shortly after intensive care admission. There is also evidence that early
extubation after OLT improves patient outcome and saves costs. However this fast
track approach needs to fulfil some important criteria, such as haemodynamic and
respiratory stability, no expected graft dysfunction, no large intraoperative blood loss,
normal pH, normothermia, uncomplicated surgery, and good teamwork between surgeons,
a naesthesiologists and intensivists. Obviously, complete recovery from NMB to avoid
respiratory failure due to PORC is mandatory and rocuronium-sugammadex use provides a
valid option, especially because extubation failure after surgery and the need for
reintubation represent an important mortality risk factor. A possible negative
consequence of sugammadex use may become apparent in the case that urgent surgery is
required within 24 hours of transplant as some residual reversal activity may still be
present due to the continual circulation of sugammadex in the blood. In this case, rapid
sequence induction is unavoidable, necessitating the use of succinylcholine with its well-
known side-effects. An increased risk of bleeding after sugammadex administration has
been reported by De Kam et al. They described an increase in INR and the aPTT ratio
time after sugammadex administration, albeit in the absence of any clinical impact. More recent evidence supports the older findings by De Kam\textsuperscript{42,43}. Our results did not reveal any increases in coagulation laboratory test values, confirming no clinically significant augmented bleeding after sugammadex has been administered. In light of the results of our study, it may be advisable to administer sugammadex with a reasonable margin of time (i.e., 15 minutes) before the actual extubation of the OLT recipient patient. A limitation to our study should also be noted; all the OLT patients included in the study were characterised by haemodynamic stability, so our findings can’t be extended to patients with poor haemodynamic conditions.

Anaesthetic management can be an important source of bias during OLT, but anaesthetic conduct in our study adhered very strictly to an internal protocol applied to all OLT. As a consequence, anaesthetic variability was minimal as the protocol regarded all aspects not related to NMB management. This ‘standardised’ anaesthetic practice in OLT translated into the lack of any statistically significant differences in intra-operative variables (such as bleeding, fluids or transfusions) between the sugammadex and neostigmine group. Additionally, all OLT were performed with the same surgical team dedicated to solid organ transplant surgery, further decreasing the potential for treatment bias, such as different surgery durations times.

**Conclusion**

The performance of sugammadex was superior to that of neostigmine in terms of recovery time in the OLT setting. Sugammadex offers anaesthetists an efficacious and safe reversal option that can facilitate a fast track recovery protocol including more frequent extubation in the operating room that may lead to improved outcomes. However, anaesthetists must bear in mind the need for longer sugammadex recovery times compared with other
surgical settings and be aware that NMT monitoring is mandatory. Further randomized clinical trials are needed to further characterize sugammadex in the setting of liver transplant, including its longer recovery time versus other surgical populations, and the potential role of steroids on its clinical effect.

**Declarations**

Ethics approval and consent to participate: this study was approved by the Institutional Ethics Committee CERU as 2016-O-015-ASUIUD. Written patient consent was obtained before the OLT procedure. Consent for publication: not applicable. Availability of data and material: the datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Competing interests: nothing to declare. Funding: no funding was received.

Author’s contribution: CD, FB, SDI, LP and GDR contributed to the study design, to collecting and analysing data and drafting the manuscript.

All authors revised and have approved the final version of the manuscript.

**Abbreviations**

OLT = orthotopic liver transplantation; NMB = neuromuscular block; NMBD = neuromuscular blocking drug; PTC = post tetanic count; PORC = post operative residual curarization; NMT = neuromuscular transmission; TOF<sub>R</sub> = train of four ratio; BMI = body mass index; MELD = model for end stage liver disease; PRC = pure red cell; FFP = fresh frozen plasma; PLT = platelets; CIT = cold ischemia time; WIT = warm ischemia time; CO = cardiac output; CI = cardiac index.

**References**

1. Madsen MV, Scheppan S, Mørk E, Kissmeyer P, Rosenberg J, Gätke MR. Influence of deep neuromuscular block on the surgeon’s assessment of surgical conditions during
1. Laparotomy: a randomized controlled double blinded trial with rocuronium and sugammadex. Br J Anaesth 2017;119:435-442. doi:10.1093/bja/aex241

2. Bruintjes MH, van Helden EV, Braat AE, et al. Deep neuromuscular block to optimize surgical space conditions during laparoscopic surgery: a systematic review and meta-analysis. Br J Anaesth 2017;118: 834-842.

3. Fernando PU, Viby-Mogensen J, Bonsu AK, Tamilarasan A, Muchhal KK, Lambourne A. Relationship between posttetanic count and response to carinal stimulation during vecuronium-induced neuromuscular blockade. Acta Anaesthesiol Scand 1987;31: 593-596.

4. Dhonneur G, Kirov K, Motamed C, et al. Post-tetanic count at adductor pollicis is a better indicator of early diaphragmatic recovery than train-of-four count at corrugator supercilii. Br J Anaesth 2007;99: 376-379.

5. Maybauer DM, Geldner G, Blobner M, et al. Incidence and duration of residual paralysis at the end of surgery after multiple administrations of cisatracurium and rocuronium. Anaesthesia 2007; 62:12-17.

6. Berg H, Roed J, Viby-Mogensen J, Mortensen CR, Engbaek J, Skovgaard LT, Krintel JJ. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 1997; 41:1095-1103.

7. Murphy GS, Szokol JW, Marymont JH, et al. Intraoperative acceleromyographic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit. Anesthesiology 2008; 109:389-398.

8. Sundman E, Witt H, Olsson R, Ekberg O, Kuylenstierna R, Eriksson LI. The incidence
and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: pharyngeal videoradiography and simultaneous manometry after atracurium. Anesthesiology 2000; 92:977-984.

9. Arbous MS, Meursing AE, van Kleef JW, et al. Impact of anesthesia management characteristics on severe morbidity and mortality. Anesthesiology 2005; 102:257-268.

10. Kotake Y, Ochiai R, Suzuki T et al. Reversal with Sugammadex in the absence of monitoring did not preclude residual neuromuscular block. Anesth Analg 2013; 117:345-351.

11. Berg H, Roed J, Viby-Mogensen J, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 1997; 41:1095–1103.

12. Grosse-Sundrup M, Henneman JP, Sandberg WS, et al. Intermediate acting nondepolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study. BMJ 2012; 345:e6329.

13. Italian Society of Anesthesia and Intensive Care. Guidelines. http://www.siaarti.it/Ricerca/buona-pratica-clinica-miorisoluzione-monitoraggio-neuromusculare-antagonismo.aspx

14. Van Miert MM, Eastwood NB, Boyd AH, Parker CJ, Hunter JM. The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. Br J Clin Pharmacol 1997; 44:139-144.

15. Blobner M, Eriksson LI, Scholz J, Motsch J, Della Rocca G, Prins ME. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled
trial. Eur J Anaesthesiol 2010; 27:874-881.

16. Geldner G, Niskanen M, Laurila P, et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia 2012; 67:991-998.

17. Biancofiore G, Tomescu DR, Mandell MS. Rapid Recovery of Liver Transplantation Recipients by Implementation of Fast-Track Care Steps: What Is Holding Us Back? Semin Cardiothorac Vasc Anesth 2018; 22:191-196.

18. Perilli V, Aceto P, Sacco T, et al. Anaesthesiological strategies to improve outcome in liver transplantation recipients. Eur Rev Med Pharmacol Sci 2016;20:3172-3177

19. Craig RG, Hunter JM. Neuromuscular blocking drugs and their antagonists in patients with organ disease. Anaesthesia 2009; 64:55-65.

20. Murphy GS, Brull SJ. Residual Neuromuscular Block: Lessons Unlearned Part I: Definitions, Incidence, and Adverse Physiologic Effects of Residual Neuromuscular Block. Anesth Analg 2010; 11:120-8.

21. Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology 2008; 109:816-824.

22. Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg 2007; 104:569-574.

23. Della Rocca G, Pompei L, Pagan De Paganis C, et al. Reversal of rocuronium induced neuromuscular block with sugammadex or neostigmine: a large observational study. Acta Anesthesiol Scand 2013; 57:1138-1145.

24. Fujita A, Ishibe N, Yoshihara T, et al. Rapid reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients with liver
25. Abdulatif M, Lotfy M, Mousa M, Afifi MH, Yassen K. Sugammadex antagonism of rocuronium-induced neuromuscular blockade in patients with liver cirrhosis undergoing liver resection: a randomized controlled study. Minerva Anestesiol. 2018 Aug;84(8):929-937.

26. Illman HL, Laurila P, Antila H, Meretoja OA, Alahuhta S, Olkkola KT. The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train-of-four monitoring. Anesth Analg 2011; 112:63-68.

27. Llaurado S, Sabate A, Ferreres E, Camprubí I, Cabrera A. Sugammadex Ideal Body Weight Dose Adjusted by Level of Neuromuscular Blockade in Laparoscopic Bariatric Surgery. Anesthesiology 2012; 117:93-8.

28. Zwiers A, van den Heuvel M, Smeets J, Rutherford S. Assessment of the potential for displacement interactions with sugammadex: a pharmacokinetic-pharmacodynamic modelling approach. Clin drug investing 2011, 31:101-11.

29. Rezonja K, Sostaric M, Vidmar G, Mars T. Dexamethasone produces dose-dependent inhibition of sugammadex reversal in in vitro innervated primary human muscle cells. Anesth Analg. 2014;118(4):755-63.

30. Rezonja K, Mars T, Jerin A, Kozelj G, Pozar-Lukanovic N, Sostaric M. Examethasone does not diminish sugammadex reversal of neuromuscular block - clinical study in surgical patients undergoing general anesthesia. BMC Anesthesiol. 2016 Oct 21;16(1):101.

31. Saleh RS and Moustafa MA. Recovery from rocuronium with sugammadex in children premedicated with dexamethasone for prevention of postoperative nausea and vomiting. Egyptian Journal of Anaesthesia 33 (2017) 1-4.

32. Ozer AB, Bolat E, Erhan OL, Kilinc M, Demirel I, Toprak GC. Sugammadex Improves
Neuromuscular Function in Patients Receiving Perioperative Steroids. Niger J Clin Pract 2018;21:139-42.

33. Kandemir T, Kandemir E, Aşkın T, Muslu S, Tuncel GO, Ünver S. Effect of Concurrent Lidocaine, Remifentanil and Methylprednisolone Use on the Clinical Effect of Sugammadex under General Anaesthesia in Rats. Turk J Anaesthesiol Reanim. 2019;47(5):392–395.

34. Zhang L, Yang L, Bi SS, Lu W, Zhang X-h, Zhai S-d, Duan L-p. Population Pharmacokinetics of Remifentanil in Patients Undergoing Orthotopic Liver Transplantation. Chinese Medical Journal 2009. 122(9):1032–1038.

35. Gao L, Ramzan I, Baker B. Rocuronium infusion requirements and plasma concentrations at constant levels of neuromuscular paralysis during three phases of liver transplantation. J Clin Anesth 2003; 15:257-266

36. Gao L, Ramzan I, Baker B. Rocuronium plasma concentrations during three phases of liver transplantation: relationship with early postoperative graft liver function. BJA 2002; 88:764–770.

37. Marcel RJ, Ramsay MA, Hein HA, et al. Duration of Rocuronium-Induced Neuromuscular Block During Liver Transplantation: A Predictor of Primary Allograft Function. Anesth Analg 1997; 84:870-874.

38. Cammu G, Bossuyt G, De Baerdemaeker L, Den Blauwen N, Struys M, Mortier E. Dose requirements and recovery profile of an infusion of cisatracurium during liver transplantation. J Clin Anesth 2002; 14:135-139.

39. Bhangui P, Bhangui P, Gupta N, Jolly AS, Bhalotra S, Sharma N, et al. Fast tracking in adult living donor liver transplantation: A case series of 15 patients. Indian J Anaesth 2018;62:127-30.

40. P. Ragonete dos Anjos Agostinil. de Fatima Santana BoinR. Martins TonellaA.M.
Heidemann dos SantosA.L. Eiras FalcãoC. Muterli LogatoL. dos Santos Roceto RattiL. Castilho de FigueiredoL.C. Martins. Mortality Predictors After Liver Transplant in the Intensive Care Unit. Transplantation Proceedings, 50, 1424e1427 (2018).

41. Pieter-Jan De Kam, Peter Grobara, Marita Prohn, Floris Höppener, Cornelis Kluft, Jacobus Burggraaf, Ronald B Langdon, Pierre Peeters. Effects of Sugammadex on Activated Partial Thromboplastin Time and Prothrombin Time in Healthy Subjects. Int J Clin Pharmacol Ther 2014; 52 (3), 227-36.

42. Iwasaki H, Renew JR, Kunisawa T, Brull SJ. Preparing for the Unexpected: Special Considerations and Complications After Sugammadex Administration. BMC Anesthesiology (2017) 17:140.

43. Dirkmann D, Britten MW, Pauling H, Weidle J, Volbracht L, Görlinger K, Peters J. Anticoagulant Effect of Sugammadex: Just an In Vitro Anesthesiology 2016; 124:1277-85.

Tables

Table 1. Demographics, biometrics, pre and postoperative liver and renal function data. Values are expressed as the mean±SD unless otherwise indicated.

Postoperative data refers to laboratory tests conducted when the patient was admitted into the ICU after LTx.

|                | Sugammadex | Neostigmine |
|----------------|------------|-------------|
|                | $n = 21$   | $n = 20$    |
| Gender         |            |             |
| female, $n$ and (%) | 7 (33)     | 8 (40)      |
|                  | Group 1 | Group 2 |
|------------------|---------|---------|
| **gender, n (%)**| 14 (67) | 12 (60) |
| **Age (years)**  | 54.1±9.8 | 54.1±10.4 |
| **Weight (kg)**  | 73.9±14.2 | 73.1±14.7 |
| **Height (m)**   | 1.7±0.1  | 1.7±0.1  |
| **BMI (kg/m²)**  | 25.2±4.2 | 25.3±3.9 |
| **Liver disease:** |         |         |
| **HBV-related cirrhosis ± HCC, n and (%)** | 2 (9.5) | 0 (0) |
| **HCV-related cirrhosis ± HCC, n and (%)** | 9 (42.8) | 6 (30) |
| **Alcohol-related cirrhosis ± HCC, n and (%)** | 6 (28.5) | 6 (30) |
| **Alcohol+HBV-related cirrhosis, n and (%)** | 1 (4.7) | 0 (0) |
| **Alcohol+HCV-related cirrhosis, n and (%)** | 0 (0) | 4 (20) |
| **HIV coexists, n and (%)** | 2 (9.5) | 2 (9.5) |
| **Other disease, n and (%)** | 3 (14.2) | 4 (19) |
| **Pre-operative liver and renal function** |         |         |
| **MELD**         | 16.8±7.3 | 21.4±9.1 |
| **AST (IU/l)**   | 67.4±39.1 | 122.8±62 |
| **ALT (IU/l)**   | 48.6±41.1 | 89.7±168.7 |
|                      | Pre-op (IU/l) | Post-op (IU/ml) | Difference |
|----------------------|---------------|-----------------|------------|
| LDH                  | 485.3±191.5   | 457.8±368.4     | 0.93       |
| TBil (mg/dl)         | 6.7±10.2      | 11.5±13.4       | 0.45       |
| DBil (mg/dl)         | 3.8±6.1       | 6.1±8.2         | 0.6        |
| GGT (IU/l)           | 155±340       | 75±74           | 0.34       |
| Albumin (mg/dl)      | 29.9±6.2      | 31±6.4          | 0.27       |
| ClCr (ml/min)        | 86.5±34.9     | 80.7±36.8       | 0.61       |

**Postoperative liver and renal function**

|                      | Pre-op (IU/l) | Post-op (IU/ml) | Difference |
|----------------------|---------------|-----------------|------------|
| AST (IU/ml)          | 1246±1060     | 1688±1508       | 0.29       |
| ALT (IU/m)           | 654±348       | 1346±1594       | 0.07       |
| LDH (IU/l)           | 2986±1699     | 3957±5804       | 0.49       |
| TBil (mg/dl)         | 4.6±2.5       | 6.9±4.6         | 0.25       |
| DBil (mg/dl)         | 3.2±2         | 4±3.2           | 0.65       |
| GGT (IU/l)           | 58±47         | 77±56           | 0.27       |
| Albumin (mg/dl)      | 19.8±8        | 21.3±6          | 0.82       |
| ClCr (ml/min)        | 86.2±30.7     | 72.2±29.1       | 0.14       |

**Abbreviations:** BMI, body mass index; MELD, Model for End-Stage Liver Disease; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; TBil, total
bilirubin; DBil, direct bilirubin; GGT, gamma glutamyl-transferase; CI Cr, estimated creatinine clearance (Cockroft-Gault formula used).

Table 2. Intraoperative data. Cardiac output and index were evaluated at reversal administration.

Values are expressed as the mean±SD.

|                         | Sugammadex (n=21) | Neostigmine (n=20) | p  |
|-------------------------|-------------------|--------------------|----|
| Duration of surgery (min) | 402±54           | 378±102            | 0.41 |
| Intra-op blood losses (ml) | 7278±6346         | 6039±5608          | 0.56 |
| PRC (ml)                | 1700±1325         | 2407±2475          | 0.28 |
| FFP transfused (ml)     | 2981±2492         | 2933±3207          | 0.9  |
| Salvaged blood transfused (ml) | 1825±1750       | 1650±2147          | 0.81 |
| Fluid balance (ml)      | 3374±2512         | 1612±1915          | 0.07 |
| CIT (h)                 | 8.3±1.9           | 8.8±2.1            | 0.73 |
| WIT (min)               | 46.6±16.5         | 39±14.8            | 0.12 |
| Total crystalloid infusion (ml) | 8585±3224   | 6582±3095          | 0.06 |
| Total albumin 4% infusion (ml) | 2612±1314   | 1982±1199          | 0.14 |
| Cardiac Output (l/min)  | 8.6±2.2           | 8.8±2.8            | 0.80 |
| Cardiac Index (l/min/m²) | 4.8±1.2           | 4.8±1.7            | 0.91 |

Abbreviations: PRC, packet red blood cell; PLT, platelets; FFP, fresh frozen plasma; CIT, cold ischaemia time; WIT, warm ischaemia time.

Table 3. Correlations between recovery time and pre, intra and postoperative values.

“Pre” refers to pre-operative while “post” to postoperative value.
|     | BMI    | MELD   | AST pre | AST post | ALT pre | ALT post | GGT pre | GGT post | CICr pre | CICr post | Length surg | Blood loss | Fluid balance |
|-----|--------|--------|---------|----------|---------|----------|---------|----------|---------|-----------|-------------|------------|---------------|
|     | -0.304 | 0.180  | -0.342  | 0.129    | -0.119  | 0.6      | 0.454   | 0.046    | 0.862   | -0.416    | 0.076       | 0.088      | 0.071         |
| MELD| 0195   | 0.454  | 0.046   | 0.862    | -0.416  | 0.076    | 0.454   | 0.046    | 0.862   | 0.076     | 0.088       | 0.076      | 0.071         |
| AST pre| 0.275 | 0.253  | 0.341   | 0.152    | -0.191  | 0.4      | 0.275   | 0.253    | 0.341   | 0.152     | -0.191      | 0.4        | 0.4           |
| AST post| 0.611 | 0.003  | 0.569   | 0.007    | 0.088   | 0.7      | 0.611   | 0.003    | 0.569   | 0.007     | 0.088       | 0.7        | 0.7           |
| ALT pre| 0.1633| 0.504  | 0.329   | 0.167    | -0.165  | 0.4      | 0.1633  | 0.504    | 0.329   | 0.167     | -0.165      | 0.4        | 0.4           |
| ALT post| 0.4960| 0.022  | 0.345   | 0.125    | 0.071   | 0.7      | 0.4960  | 0.022    | 0.345   | 0.125     | 0.071       | 0.7        | 0.7           |
| GGT pre| -0.061| 0.815  | 0.335   | 0.186    | 0.429   | 0.0      | -0.061  | 0.815    | 0.335   | 0.186     | 0.429       | 0.0        | 0.0           |
| GGT post| -0.242| 0.317  | 0.037   | 0.878    | -0.052  | 0.8      | -0.242  | 0.317    | 0.037   | 0.878     | -0.052      | 0.8        | 0.8           |
| CICr pre| 0.378 | 0.090  | 0.296   | 0.191    | -0.124  | 0.6      | 0.378   | 0.090    | 0.296   | 0.191     | -0.124      | 0.6        | 0.6           |
| CICr post| -0.232| 0.311  | -0.176  | 0.445    | 0.019   | 0.5      | -0.232  | 0.311    | -0.176  | 0.445     | 0.019       | 0.5        | 0.5           |
| Length surg| 0.293 | 0.198  | 0.357   | 0.113    | 0.570   | 0.6      | 0.293   | 0.198    | 0.357   | 0.113     | 0.570       | 0.6        | 0.6           |
| Blood loss| 0.423 | 0.063  | 0.355   | 0.123    | 0.239   | 0.3      | 0.423   | 0.063    | 0.355   | 0.123     | 0.239       | 0.3        | 0.3           |
| Fluid balance| 0.293 | 0.270  | 0.209   | 0.436    | -0.131  | 0.6      | 0.293   | 0.270    | 0.209   | 0.436     | -0.131      | 0.6        | 0.6           |
|                | CIT     | WIT     | Tot NMBA | Crystalloids | Colloids | CO      | Cl       |
|----------------|---------|---------|----------|--------------|----------|---------|----------|
|                | -0.151  | 0.461   | 0.271    | 0.093        | 0.502    | 0.449   | 0.404    |
|                | 0.515   | 0.036   | 0.235    | 0.697        | 0.024    | 0.047   | 0.086    |
|                | -0.152  | 0.372   | 0.182    | 0.045        | 0.271    | 0.363   | 0.349    |
|                | 0.511   | 0.097   | 0.430    | 0.852        | 0.248    | 0.115   | 0.143    |
|                | -0.084  | -0.054  | 0.135    | 0.199        | 0.041    | -0.051  | -0.062   |
|                | 0.7     | 0.8     | 0.5      | 0.4          | 0.8      | 0.8     | 0.8      |

Abbreviations: BMI, body mass index; MELD, Model for End-Stage Liver Disease; CIT, cold ischaemia time; WIT, warm ischaemia time; ClCr, clearance creatinine (Cockroft Gault); CO, cardiac output; CI, cardiac index; NMBA, neuromuscular blocking agent; AST, alanine aspartate transferase; alanine amino transferase; GGT, gamma glutamyl transferase.

Figures
Figure 1

Study flow-chart according to CONSORT. Abbreviations: LTx, orthotopic liver transplantation; GFR, glomerular filtration rate.
Figure 2

Recovery time for sugammadex and neostigmine. Mean value was 9.4 vs 34.6 minutes for sugammadex and neostigmine respectively (p<0.0001). Box plot comprehends median and interquartile (25th-75th) range, cross inside box plot represents mean value and whiskers represent minimum and maximum value. ° represents an outlier patient that was not taken into account when calculating recovery time because of its value > 100 minutes.

Supplementary Files

This is a list of supplementary files associated with the primary manuscript. Click to download.

CONSORT 2010 Checklist BMC ANESTH.doc